Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 2 1

Status

Active not recruiting 3Recruiting 2

Sponsor Class

INDUSTRY 3OTHER_GOV 1OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5Head & Neck 1Gynecologic 1

Conditions

Breast Neoplasms 72Neoplasms 7Neoplasm Metastasis 7Breast Diseases 5Neoplasms by Site 3Carcinoma, Intraductal, Noninfiltrating 3Breast Neoplasms, Male 3Ovarian Neoplasms 2Endometrial Neoplasms 2Breast Neoplasm Female 2Advanced Breast Cancer 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Diseases 1Sexual Dysfunctions, Psychological 1Low Grade Serous Ovarian Cancer 1Locoregional Recurrence 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1HER2-positive Breast Cancer 1HER2 Negative Breast Cancer 1Granulosa Cell Ovarian Cancer 1Fallopian Tube Neoplasms 1Endometrial Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Lobular 1Carcinoma, Ductal, Breast 1Breast Carcinoma In Situ 1

Interventions

Anastrozole 5palbociclib 4abemaciclib 3Trastuzumab 3Fulvestrant 3ribociclib 2pertuzumab 2exemestane 2Tamoxifen 2Letrozole 2Gonadotropin-Releasing Hormone 2AZD9833 2trastuzumab deruxtecan 1taxane 1elacestrant 1dalpiciclib 1STX-478 1RAD1901 1Metformin 1Leflunomide 1Imlunestrant 1Genotype 1Body Height 1Blood Specimen Collection 1Blood Pressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Breast Diseases × Anastrozole × 1 year × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07581834 2026-05-12

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

Fujian Cancer Hospital

Phase 2 Recruiting
2,000 enrolled
Breast

Breast Diseases, Breast Neoplasms

NCT04964934 2026-04-21

SERENA-6

AstraZeneca

Phase 3 Active not recruiting
315 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT04711252 2025-10-14

SERENA-4

AstraZeneca

Phase 3 Active not recruiting
1,370 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Skin Diseases

NCT03304080 2025-07-18

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

Icahn School of Medicine at Mount Sinai

Phase 1/2 Active not recruiting
44 enrolled
Breast

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡